ReveraGen BioPharma Inc Initiates VISION-DMD Phase 2a Study for Treatment of Duchenne Muscular Dystrophy

Published on 08/09/2016

Enrolment has begun in the phase 2a clinical trial of the orphan drug vamorolone (VBP15) in the treatment of ambulatory boys with Duchenne muscular dystrophy (DMD). The trial, sponsored by ReveraGen BioPharma, is part of the Horizon 20020-funded VISION-DMD project (An Innovative Steroid-like Intervention on DMD), in which ECRIN is involved as a partner.

In addition to the newly initiated phase 2a trial, VISION-DMD includes a phase 2b study. The studies aim to assess the safety and toxicity (phase 2a) and safety and efficacy (phase 2b) of VBP15 as a new therapy to revolutionise care for patients with DMD (a rare recessive X-linked form of muscular dystrophy).

ECRIN is responsible in particular for various components of the phase 2b study, working in close collaboration with the sponsor (Reveragen Biopharma Limited), the University of Newcastle Upon Tyne (UNEW), and patient organisations.

To read the full press release on the ReveraGen Biopharma website, click here

To learn more about the VISION-DMD project, see here


EU flag VISION-DMD has received funding from the European Union’s Horizon 2020 research and innovation programme (grant agreement No 667078) and the US National Institutes of Health under grant agreement NINDS R44 NS095423.